Comments
Natco Pharma Limited has received Emergency Use approval for Baricitinib tablets from Central Drugs Standard Control Organization (CDSCO) in India.
Baricitinib in combination with Remdesivir, is used for treatment of Covid-19 positive patients.
Hyderabad-based Natco will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the Pandemic.
The company is ready to launch the product this week, so as to make it available to suffering patients across India, the release added.
Related Stories
Natco Pharma up 3% on emergency approval for Baricitinib tablets for Covid-19 treatment
Natco Pharma was trading at ₹927.60 on the BSE
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.